Phesgo and Tecentriq Performance and Approvals
2023: Upcoming newsflow
Pharma
Tiragolumab + Tecentriq in 1L PDL 1+ NSCLC
Tiragolumab + Tecentriq + chemo in 1L
Esophageal
Glofitamab + GemOx in 2L+ DLBCL
Lunsumio + Polivy in 2L+ DLBCL*
Crovalimab in PNH
Roche
CCM Vertical
LightCycler Pro
Diagnostics
Modular transportation system, integrated
into existing cobas connection modules
Flexible real-time PCR instrument with dual
IVD and Research mode
Anti-HEV IgM: Immunoassay aiding in
diagnosis of acute HEV infection in clinic.
Anti-HEV IgG: Immunoassay aiding in
detection of a recent or past HEV infection
Immunoassay aiding in diagnosis,
monitoring and predicting treatment
response for patients with hepatitis B
Immunoassay with dedicated claim aiding in
diagnosis of sepsis in neonates
Tecentriq + Avastin in adjuvant HCC
Tecentriq in adjuvant SCCHN
Delandistrogene moxeparvovec
(SRP-9001) in DMD
Tecentriq+chemo in adjuvant TNBC
×
Anti-HEV IgG and
Anti-HEV IgM
Tecentriq neoadjuvant/adjuvant TNBC
Ocrevus 6m SC in RMS/PPMS
Phesgo OBI in HER2+ BC
TNKase in Stroke
HBeAg Quant
Alecensa in adjuvant ALK+ NSCLC
Susvimo in DME
Venclexta + azacitidine in 1L high risk MDS
Susvimo in DR
IL-6 Neonatal sepsis
(claim extension)
Venclexta + dexamethasone
in R/R MM (t11;14)
Xolair in Food allergy
Neuroscience
Ophthalmology
Oncology/Hematology
Immunology
DME=diabetic macular edema; DLBCL-diffuse large B-cell lymphoma; NSCLC-non-small cell lung cancer; HCC-hepatocellular carcinoma; MM-multiple myeloma; PCR-polymerase chain reaction; SC=subcutaneous; DR-diabetic
retinopathy; RMS=relapsing MS; PPMS=primary progressive MS; PNH=Paroxysmal nocturnal hemoglobinuria; TNBC-triple negative breast cancer; SCCHN-squamous cell carcinoma of head and neck; DMD=Duchenne muscular
dystrophy; OBI-on-body injector; BC=breast cancer; MDS-Myelodysplastic syndrome; R/R=relapsed/refractory; IVD-in vitro diagnostics; HEV=Hepatitis E Virus; *Results are event-driven, read-outs expected 2023/24
12
1View entire presentation